151 related articles for article (PubMed ID: 16398596)
1. Omega-3 fatty acids for the treatment of cancer cachexia: issues in designing clinical trials of dietary supplements.
Harle L; Brown T; Laheru D; Dobs AS
J Altern Complement Med; 2005 Dec; 11(6):1039-46. PubMed ID: 16398596
[TBL] [Abstract][Full Text] [Related]
2. Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients.
Brown TT; Zelnik DL; Dobs AS
Int J Gastrointest Cancer; 2003; 34(2-3):143-50. PubMed ID: 15361649
[TBL] [Abstract][Full Text] [Related]
3. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.
Fearon KC; Von Meyenfeldt MF; Moses AG; Van Geenen R; Roy A; Gouma DJ; Giacosa A; Van Gossum A; Bauer J; Barber MD; Aaronson NK; Voss AC; Tisdale MJ
Gut; 2003 Oct; 52(10):1479-86. PubMed ID: 12970142
[TBL] [Abstract][Full Text] [Related]
4. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.
Cerchietti LC; Navigante AH; Castro MA
Nutr Cancer; 2007; 59(1):14-20. PubMed ID: 17927497
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 fatty acids in cancer.
Laviano A; Rianda S; Molfino A; Rossi Fanelli F
Curr Opin Clin Nutr Metab Care; 2013 Mar; 16(2):156-61. PubMed ID: 23299701
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473.
Burns CP; Halabi S; Clamon GH; Hars V; Wagner BA; Hohl RJ; Lester E; Kirshner JJ; Vinciguerra V; Paskett E
Clin Cancer Res; 1999 Dec; 5(12):3942-7. PubMed ID: 10632323
[TBL] [Abstract][Full Text] [Related]
7. Relevance of Dietary Supplement Use in Gastrointestinal-Cancer-Associated Cachexia.
Yoon SL; Grundmann O
Nutrients; 2023 Jul; 15(15):. PubMed ID: 37571328
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 polyunsaterated fatty acids improve quality of life and survival, but not body weight in cancer cachexia: A systematic review and meta-analysis of controlled trials.
Jin X; Xu XT; Tian MX; Dai Z
Nutr Res; 2022 Nov; 107():165-178. PubMed ID: 36283229
[TBL] [Abstract][Full Text] [Related]
9. Omega-3 fatty acid supplements for cancer-associated weight loss.
Jatoi A
Nutr Clin Pract; 2005 Aug; 20(4):394-9. PubMed ID: 16207679
[TBL] [Abstract][Full Text] [Related]
10. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
11. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
12. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia.
Barber MD; Fearon KC; Tisdale MJ; McMillan DC; Ross JA
Nutr Cancer; 2001; 40(2):118-24. PubMed ID: 11962246
[TBL] [Abstract][Full Text] [Related]
13. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project.
Ries A; Trottenberg P; Elsner F; Stiel S; Haugen D; Kaasa S; Radbruch L
Palliat Med; 2012 Jun; 26(4):294-304. PubMed ID: 21865295
[TBL] [Abstract][Full Text] [Related]
14. Compliance with nutrition prescription improves outcomes in patients with unresectable pancreatic cancer.
Bauer J; Capra S; Battistutta D; Davidson W; Ash S;
Clin Nutr; 2005 Dec; 24(6):998-1004. PubMed ID: 16140426
[TBL] [Abstract][Full Text] [Related]
15. The Infant Fish Oil Supplementation Study (IFOS): design and research protocol of a double-blind, randomised controlled n--3 LCPUFA intervention trial in term infants.
Meldrum SJ; D'Vaz N; Dunstan J; Mori TA; Prescott SL
Contemp Clin Trials; 2011 Sep; 32(5):771-8. PubMed ID: 21718804
[TBL] [Abstract][Full Text] [Related]
16. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.
Kraft M; Kraft K; Gärtner S; Mayerle J; Simon P; Weber E; Schütte K; Stieler J; Koula-Jenik H; Holzhauer P; Gröber U; Engel G; Müller C; Feng YS; Aghdassi A; Nitsche C; Malfertheiner P; Patrzyk M; Kohlmann T; Lerch MM
Nutr J; 2012 Jul; 11():52. PubMed ID: 22824168
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
Gordon JN; Trebble TM; Ellis RD; Duncan HD; Johns T; Goggin PM
Gut; 2005 Apr; 54(4):540-5. PubMed ID: 15753541
[TBL] [Abstract][Full Text] [Related]
18. A triple-masked, two-center, randomized parallel clinical trial to assess the superiority of eight weeks of grape seed flour supplementation against placebo for weight loss attenuation during perioperative period in patients with cachexia associated with colorectal cancer: a study protocol.
Malta FAPS; Gonçalves DC
Front Endocrinol (Lausanne); 2023; 14():1146479. PubMed ID: 38313843
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients.
Barber MD; Preston T; McMillan DC; Slater C; Ross JA; Fearon KC
Clin Sci (Lond); 2004 Apr; 106(4):359-64. PubMed ID: 14624668
[TBL] [Abstract][Full Text] [Related]
20. Nutritional treatment of cancer cachexia in rats. Use of a diet formulated with a crayfish enzymatic extract.
Cremades O; Parrado J; Jover M; Collantes de Terán L; Gutiérrez JF; Bautista Palomas JD
Eur J Nutr; 2007 Sep; 46(6):347-53. PubMed ID: 17676424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
